TABLE 8

Medications

Subjects1465
No LABA/ICS22 (1.5)
Inhaled corticosteroids only#136 (9.3)
 <500 μg·day−121 (15.4)
 500–1000 μg·day−141 (30.1)
 1000–2000 μg·day−157 (41.9)
 >2000 μg·day−115 (11)
LABAs only106 (7.2)
ICS/LABA combination#1326 (90.5)
 <500 μg·day−162 (4.7)
 500–1000 μg·day−1419 (31.6)
 1000–2000 μg·day−1590 (44.5)
 >2000 μg·day−1253 (19.1)
Anticholinergic treatment498 (34)
Antileukotriene (montelukast)759 (52.2)
Long-term oral corticosteroid therapy245 (16.8)
 Mean daily dose mg19.4±34.2
Anti-IgE (omalizumab)390 (26.8)
 Dose mg347±155.3
 Frequency of treatment
  Every 2 weeks180 (46.9)
  Every 4 weeks204 (53.1)
  Missing data6
 Duration of treatment years3.1±2.6
Theophylline97 (6.7)
Other therapies
 Long-term azithromycin84 (5.6)
 Antihistamine655 (45)
 Antidepressants121 (8.3)
 β-blocker26 (1.8)
 Anti-GORD483 (33.2)
 Postmenopausal hormone therapy14 (1.5)
 Desensitisation in the previous 5 years54 (3.7)
 Alternative medicine84 (5.8)
Patient adherence level according to physician
 High1063 (78.5)
 Medium245 (18.1)
 Low47 (3.5)
Adherence level MMAS-4 score3.4±1
 Adherent patient (score=4)835 (64.8)
 Non-adherent patients (score <4)454 (35.2)
 Missing data78

Data are presented as n, n (%) or mean±sd. LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; Ig: immunoglobulin; GORD: gastro-oesophageal reflux disease; MMAS-4: four-item Morisky Medication Adherence Assessment Scale. #: doses are presented as equivalent beclomethasone dipropionate; : doses are presented as equivalent prednisolone.